Buradasınız

Anasayfa » Content

Bronş karsinomu ve immünite

Bronchial carcinoma and immunity

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The levels of serum immunglobulins were measured in 30 subjects diagnosed bronchial carcinoma at Atatürk Universty chest disease's department in order to determine humoral and cellular immunity. Tüberkülin skin tests were made. As a result, regardless of the stage and type, the levels of serum immunglobulins were high. Especially negative results of tuberculin skin tests were significantly high in extensive stage carcinomas. This result indicated that there was a correlation between the stage and sellular immunity. [Journal of Turgut Özal Medical Center 2(2): 166-168,1995]
Bookmark/Search this post with
Abstract (Original Language): 
Atatürk Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı kliniğinde bronş karsinomu tanısı konan 30 olguda hücresel ve humoral immüniteyi değerlendirmek amacıyla serum immünglobulin düzeyleri ölçüldü ve tüberkülin cilt testi yapıldı. Sonuçta serum immünglobulin düzeyleri yüksek olmakla birlikte hücre tipi ve evreye göre farklılık göstermezken özellikle ileri evredeki tümörlerde PPD negatifliği daha yüksek oranda saptandı. Bu sonuç akciğer kanserinde evre ile hücresel immünitenin ilişkili olduğunu gösterdi. [Turgut Özal Tıp Merkezi Dergisi 2(2): 166-168,1995]
FULL TEXT (PDF): 
PDF icon arastirmax-brons-karsinomu-immunite.pdf
  • 22
166-168
  • Turkish

REFERENCES

References: 

1. Larney DN, Deleig L. Lung cancer biology. Semin Oncol 1938:15:199.
2. Bann PA. Lung cancer understanding of biology. Diagnosis, staging and treatment. Bristol Myers Company Ewansuille. USA 1988:3.
3. Pillai MR, Balarom P, Padmonobhin TK, et al. Immunocompetence in lung cancer. Cancer 1989; 64:1853-4.
4. Waldmann TA, Strober W, Blaese RM. Immunodeficieny disease and malignancy. Various immunolojic deficiencies of man and the role of immune process in the control of malign disease Ann intern Med 1972;77:605.
5. Stiehm ER, Ammann AJ, Barnett EV, et al. Diseases of cellular immunity. Ann Intern Med 1972;77:101.
6. Roth JA, Eliber FR, Nizze JA, Morton DL. Lack of correlation between skin reactivity to dinitrochlorobenzene and croton oil in patient with cancer. N Eng J Med 1975;293:388-9.
7. Maisel RH, Ogura JH. Dinitrocholorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer. Ann Otol 1976; 85:517-22.
8. Heiss LI, Palmer DL. Anergy in patient with leukocytosis. Am J Med 1974;56:323-32.
9. Palmer DL, Reed WP. Delayed hypersensitivity skin tenting. l.Response rates in a hospitalized population. J Infect Dis 1974;130:138-43.
10. Strauss BJ, Bridges BA, Greaves M, Hall-Smith P, Price M, Vella-Briffa D. Inhibition of delayed hypersensivity reaction in skin (DNCB test) by 8-metoxypsoralen photochemotherapy. Lancet 1980;2:556-9.
11. Kalpaklıoğlu AF, Bilgen G, Başer Y. Akciğer kanserlerinde hücresel immünite bozukluğunun E-rozet formasyonu yöntemiyle değerlendirilmesi. Solunum Hastalıkları 1993;412:181-9.
12.
Brugerola
s A, Takita H. immunolojic status in lung cancer. Chest 1993;427:23.
13. Bolton PM, Mander AM, Davidson JM, et al. Cellular immunity in cancer: Comparison of delayed hypersensitivity skin tests in there common causes. Br Med J 1975;3:18.
15.
Bilgi
ç H. Tüberküloz Epidemiyolojisi. Editör. Kocabaş A. Tüberkülozun kliniği ve kontrolü. Adana 1991:430.
15. Ginn LC, Goldenheim PD, Miller LG, et al. T lympcyte subsets in smoking and lung cancer: Analysis by monoclonal antibodies and flow cytometry. Am Rev Resp Dis 1982;126:265-8.

Thank you for copying data from http://www.arastirmax.com